Average Bioavailability Assessment

Average Bioavailability Assessment is a statistical method used in bioequivalence studies to quantify the relative systemic exposure of a drug formulation by comparing the mean area under the plasma concentration-time curve (AUC) and maximum concentration (Cmax) between test and reference products under standardized conditions.

16

Publications

3.2K

Citations

45

Authors

23

Institutions

Publications per year

2017–2026

1

Authors

45

  1. JL
    Jen‐pei Liu

    National Health Research Institutes, Taiwan

    2 publications · 50 citations

    2

    h-index

  2. DJ
    Donald J. Schuirmann

    United States Food and Drug Administration, United States

    2 publications · 2.6K citations

    2

    h-index

  3. JV
    Jouni Vuorinen

    University of Turku, Finland

    2 publications · 29 citations

    2

    h-index

  4. CB
    C. Button

    University of Pretoria, South Africa

    1 publications · 33 citations

    1

    h-index

  5. BM
    B. Martin

    Université de Bordeaux, France

    1 publications · 11 citations

    1

    h-index

1–5 of 45

Venues

  1. Statistics in Medicine

    4 publications · 246 citations

    4

    h-index

  2. 2

    h-index

  3. Biological and Pharmaceutical Bulletin

    1 publications · 13 citations

    1

    h-index

  4. PubMed

    Repository · 1 publications · 25 citations

    1

    h-index

  5. 1

    h-index

1–5